

## Consolidated disclosure of related party transactions and balances for the half year ended March 31, 2019

### A. Relationships -

#### Category I: Entity having significant influence over the Company:

Lupin Investments Pvt. Limited

#### Category II: Jointly Controlled Entity:

YL Biologics Ltd., Japan

#### Category III: Key Management Personnel (KMP)

|   |  |
|---|--|
| Mrs. Manju D.Gupta                              | Chairperson                                  |
| Dr. Kamal K. Sharma                             | Vice Chairman                                |
| Ms.Vinita Gupta                                 | CEO  |
| Mr. Nilesh Deshbandhu Gupta                     | Managing Director                            |
| Mr.Ramesh Swaminathan (up to December 11, 2018) | Chief Financial Officer & Executive Director |
| Dr. Vijay Kelkar (up to March 28, 2019)         | Director                                     |
| Mr. R. A. Shah                                  | Director                                     |
| Mr. Richard Zahn                                | Director                                     |
| Dr. K. U. Mada                                  | Director                                     |
| Mr. Dileep C. Choksi                            | Director                                     |
| Mr. Jean Luc Belingard                          | Director                                     |
| Mr. R.V. Satam                                  | Company Secretary                            |

#### Category IV: Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)

Ms. Kavita Gupta  
Dr. Anuja Gupta  
Dr. Richa Gupta  
Ms. Shefali Nath Gupta  
Miss Veda Nilesh Gupta  
D. B. Gupta (HUF)  
Gupta Family Trust  
Lupin Human Welfare and Research Foundation  
Lupin Foundation  
Matashree Gomati Devi Jana Seva Nidhi  
Polynova Industries Limited  
Zyma Properties Pvt. Limited  
Shuban Prints  
S N Pharma  
Team Lease Services Limited

**B. Transactions with the Related Parties:****(₹ in million)**

| Sr. No. | Transactions   | For the six months ended 31.03.2019 |
|---------|--|-------------------------------------|
| 1       | <b>Purchases of Goods</b><br>Others  | 118.2                               |
| 2       | <b>Sale of Goods</b><br>Jointly Controlled Entity  | 27.6                                |
| 3       | <b>License Fees Received</b><br>Jointly Controlled Entity                                | 212.4                               |
| 4       | <b>Sale of Equipment</b><br>Others   | 0.1                                 |
| 5       | <b>Rent Paid</b><br>Others   | 39.3                                |
| 6       | <b>Donations Paid</b><br>Others  | 152.6                               |
| 7       | <b>Services Received (Expense)</b><br>Jointly Controlled Entity<br>Others                | 146.5<br>61.6                       |
| 8       | <b>Expenses incurred on our behalf reimbursed</b><br>Jointly Controlled Entity<br>Others | 95.6<br>1.9                         |
| 9       | <b>Expenses Recovered / Rent Received</b><br>Others                                      | 1.9                                 |
| 10      | <b>Remuneration, Commission, Advisory and Sitting Fees</b><br>Key Management Personnel   | 82.8                                |

**C. Balances due from/to the Related Parties:****(₹ in million)**

| Sr. No. | Balances   | As at 31.03.2019 |
|---------|--|------------------|
| 1       | <b>Deposits paid under Leave and Licence arrangement for Office Premises</b><br>Others     | 43.4             |
| 2       | <b>Trade Receivables</b><br>Jointly Controlled Entity                                      | 109.9            |
| 3       | <b>Trade Payables</b><br>Others  | 29.2             |
| 4       | <b>Deposits received under Leave and Licence arrangement for Office Premises</b><br>Others | 0.1              |

Transactions and balances with Jointly Controlled Entity have been reported at full value.